Sebastian Gensior

Regulator Depth/Specificity of AI Sandbox (focus on AI in drug development) Scope of AI Experimentation (breadth of permitted AI use cases) Maturity of Sandbox (planned → operational) Stakeholder Engagement (industry/academia involvement, transparency) Regulatory Impact (influence on guidance/policy) FDA (USA) 3/5: No single "AI sandbox" label,

The landscape for Special Purpose Acquisition Companies (SPACs) within the healthcare and biotechnology sectors in mid-2025 presents a complex, dual narrative. While there is indeed a discernible uptick in SPAC initial public offering (IPO) volume compared to the immediate past, this resurgence is fundamentally distinct from the speculative frenzy

Global pharmaceutical and biotech deals remain subdued during August week The week of August 4-9, 2025 marked an unusually quiet period for pharmaceutical and biotech dealmaking globally, with only 16 confirmed transactions totaling approximately $2.3 billion in disclosed values across all markets. The Asia-Pacific region dominated with

In the late 19th century, traveling medicine shows peddled cure-all elixirs with flamboyant claims. Today’s equivalent in biotech is the “AI-powered” drug discovery platform. Startups boasting deus ex machina algorithms promise to conjure new cures in silico, compressing years of laboratory toil into months of number-crunching.

BridgeBio Pharma stands at a critical inflection point in its evolution from development-stage biotech to commercial pharmaceutical company. With the November 2024 FDA approval of Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM), the company has entered the highly competitive cardiovascular therapeutics market while maintaining a robust late-stage

Overview and Financial Model LifeArc is a UK-based medical research charity with a unique financial model, operating more like an investment fund backed by past drug royalties rather than through ongoing donations. The charity finances itself via a large endowment-like investment portfolio, seeded by monetizing a blockbuster drug

Habana Gaudi2 and Gaudi3 Accelerators Intel’s Gaudi2 (2022) and Gaudi3 (2024) AI accelerators target training of large models with high cost-efficiency. Gaudi2 has demonstrated competitive performance, delivering up to 2.4× faster deep learning throughput than NVIDIA’s A100 GPU. The newer Gaudi3, with 128 GB of HBM2e

Advanced Micro Devices (AMD) has emerged as a significant challenger to NVIDIA's long-standing dominance, pursuing an aggressive strategy to capture market share in the lucrative biotech AI sector. This comprehensive analysis examines AMD's current position, technological capabilities, competitive dynamics, and future prospects in biotechnology applications.

The convergence of artificial intelligence (AI), accelerated computing hardware, and vast biological datasets is transforming healthcare and biotech into a high-tech industry. NVIDIA – best known for its graphics processing units (GPUs) – has aggressively moved into this space, aiming to power everything from drug discovery to medical diagnostics. In fact,

Global pharmaceutical and biotech deals surge with $15+ billion in transactions The pharmaceutical and biotechnology sectors witnessed significant deal activity during the week of July 28 to August 2, 2025, with over 20 major transactions totaling more than $15 billion in disclosed and potential value. The week marked a notable